EichorEICHOR
Condition: Acute Leukemias Synced from ClinicalTrials.gov · August 09, 2026

Recruiting studies: Acute Leukemias

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
Phase 1 · 1 location(s) · Liping Dou · NCT07677878Mercaptopurine Therapeutic Drug Monitoring to Optimize the Maintenance Phase of Childhood ALL
Phase N/A · 4 location(s) · IRCCS Burlo Garofolo · NCT05811845A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cel
Phase 2/Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06860269Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment o
Phase 1 · 2 location(s) · Catherine Bollard · NCT02203903Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myelo
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03214562Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced In
Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT07548983The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Phase 1/Phase 2 · 17 location(s) · Lin BioScience, Inc · NCT05756322PTCy and ATG for MSD and MUD Transplants
Phase 1/Phase 2 · 1 location(s) · Instituto Nacional de Cancer, Brazil · NCT06299462NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05262673Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)
NA · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT07634653Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Phase 3 · 124 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05327894Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT07144020Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase 1 · 1 location(s) · CytoCares Inc · NCT06037018MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · 347 location(s) · National Cancer Institute (NCI) · NCT05564390Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07101497Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Phase 2 · 3 location(s) · Montefiore Medical Center · NCT05184842A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Phase 1/Phase 2 · 8 location(s) · Chordia Therapeutics, Inc. · NCT05732103A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Maligna
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532203CAR-T Immunotherapy Targeting CD19- ALL
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04016129VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06220162Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Phase 1 · 16 location(s) · New York Medical College · NCT04972942Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Phase 3 · 48 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04168502HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Phase 1 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT06594445Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel
Phase 2 · 7 location(s) · National Cancer Institute (NCI) · NCT07437950ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Phase 1 · 4 location(s) · Marlise Luskin, MD · NCT03595917Venetoclax Combined With Azactidine in the Treatment of ALAL
Phase 2 · 1 location(s) · Sheng-Li Xue, MD · NCT05901974Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi
NA · 1 location(s) · University of Washington · NCT06710418Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06364423A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leuke
Phase 1/Phase 2 · 2 location(s) · University of Chicago · NCT06207123
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.